Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01227187 · ClinicalTrials.gov registry record · Phase 2

Safety and Dose Finding Study of Xigris in Hemodialysis Patients

A Phase 2 study of End Stage Renal Disease, sponsored by George Washington University.

Completed
Registry status
Phase 2
Development phase
12
Enrollment target
1
Study location

NCT01227187 is a Phase 2 study of End Stage Renal Disease that has completed, run by George Washington University. The registered enrollment target is 12 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01227187, a Phase 2 study of End Stage Renal Disease, has completed, sponsored by George Washington University.

COMPLETED
Registry status
Phase 2
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to assess the safety of Xigris (Drotrecogin alfa) as an anticoagulant at different dose levels during dialysis treatment in patients with End Stage Renal Disease (ESRD).

Conditions Studied

End Stage Renal Disease

Interventions

  • DRUG Drotrecogin alfa activated (Xigris)

Study Locations (1)

District of Columbia

  • The George Washington University Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2008-10
Est. Completion 2010-12
Phase Phase 2

Sponsor

George Washington University

133 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01227187

The ClinicalTrials.gov registry entry for NCT01227187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Drotrecogin alfa activated (Xigris) is the first listed.

NCT01227187 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT01227187 about?

NCT01227187 is a clinical study titled "Safety and Dose Finding Study of Xigris in Hemodialysis Patients". The purpose of the study is to assess the safety of Xigris (Drotrecogin alfa) as an anticoagulant at different dose levels during dialysis treatment in patients with End Stage Renal Disease (ESRD).

What is the current status of trial NCT01227187?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2008-10. Estimated completion is 2010-12.

What conditions does trial NCT01227187 study?

This clinical trial studies the following conditions: End Stage Renal Disease.

What interventions are being tested in trial NCT01227187?

The interventions under investigation include: Drotrecogin alfa activated (Xigris) (DRUG).

Who is sponsoring clinical trial NCT01227187?

This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01227187 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

End Stage Renal Disease

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.